课题基金 / 基金详情

EXPRESSION OF THE OX40/GP34 SYSTEM IN CUTANEOUS GRAFT VERSUS HOST DISEASE

EXPRESSION OF THE OX40/GP34 SYSTEM IN CUTANEOUS GRAFT VERSUS HOST DISEASE
OX40/GP34 系统在皮肤移植物抗宿主疾病中的表达
批准号:
6235808
负责人:
ROBERT A SWERLICK
金额:
$5.56万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-03-01 至 1998-02-28

项目摘要

项目成果

ROBERT A SWERLICK的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The OX40 receptor and gp34 ligand system is a recently characterized receptor/ligand pair. First identified on activated rat CD4+ cells, OX40 has been demonstrated to be a 50kD cell surface glycoprotein whose expression in human blood seems to be limited to activated T-cells. Human OX40 is a member of the nerve growth factor receptor/tumor necrosis factor family whose members also include fas/APO-1, CD40, CD27, CD30, and 4-1BB/ILA antigens. These molecules are involved with regulation of cell growth, differentiation and apoptosis. Gp34 was recently discovered to be the ligand for human OX40. It is a type II membrane glycoprotein expressed on HTLV-1 infected T-cell lines. Gp34 is also expressed on EBV-infected B-cells, activated peripheral circulating B-cells, and it appears to mediate binding of activated T- cells to human dermal microvascular endothelial cells. The exact function of this receptor/ligand pair is unclear. However, recent studies have shown that in addition to cell adhesion, OX40/gp34 crosslinking results in propagation of T-cell proliferation, B-cell proliferation and differentiation into antibody producing plasma cells, and an alteration in cytokine secretion. The goal of this proposed investigation is to characterize the distribution of this receptor/ligand pair in murine and human skin and to determine its role in the pathogenesis of cutaneous graft versus host disease (GvHD).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CORE--MOLECULAR ANALYSIS
  • 批准号:
    6645886
  • 项目类别:
  • 资助金额:
    $6.18万
  • 财政年份:
    2002
  • 负责人:
    ROBERT A SWERLICK
  • 依托单位:
Annual Dermatology Resident Retreat
Annual Dermatology Resident Retreat
Annual Dermatology Resident Retreat
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2016
  • 负责人:
    陈昊
  • 依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 项目类别:
    面上项目
  • 资助金额:
    73.0万元
  • 批准年份:
    2014
  • 负责人:
    董家鸿
  • 依托单位: